Publicaciones en las que colabora con Emilio José Sanz Álvarez (65)

2026

  1. A Comparative Analysis of Fatal Outcomes in 5,370 Geriatric Versus 12,254 Nongeriatric Adult Patients: A Clozapine Study in VigiBase

    The American Journal of Geriatric Psychiatry, Vol. 34, Núm. 4, pp. 591-601

  2. A study in VigiBase of clozapine fatal outcomes in 7874 middle-aged versus 4380 young adults

    Psychiatry Research, Vol. 359, pp. 117037

  3. An international adult guideline for making Clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and Clozapine levels

    Chinese Journal of Psychiatry, Vol. 59, Núm. 2, pp. 87-113

  4. Changing your perspective on fatal outcomes in clozapine-treated patients. They do not die of agranulocytosis

    Asian Journal of Psychiatry

  5. Clozapine and Suicide in VigiBase: Most Important Fatal Outcome in Young Males and Differences Between Attempted and Completed Suicide

    Journal of clinical psychopharmacology, Vol. 46, Núm. 1, pp. 5-15

2025

  1. Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior literature

    Expert Opinion on Drug Safety, Vol. 24, Núm. 11, pp. 1301-1311

  2. Clozapine pharmacovigilance in Croatia: Underreporting of specific adverse drug reactions and excellent reporting of suicide attempts: Clozapine Croatia suicide

    Psychiatry Research, Vol. 347

  3. Clozapine-treated patients and myocardial infarction in adults: a pharmacovigilance study in VigiBase interpreted in the context of the literature

    Expert Opinion on Drug Safety

  4. Evaluating the adverse drug reactions to clozapine in populations of children and adolescents: insights from VigiBase data

    European Child and Adolescent Psychiatry, Vol. 34, Núm. 7, pp. 2083-2091

  5. Fatal Outcomes in Use of Clozapine: A VigiBase Study of 6402 Women and 11,222 Men

    Journal of clinical psychopharmacology, Vol. 45, Núm. 6, pp. 547-553

  6. Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I A Review of the Pharmacokinetic Literature and Proposed Changes

    Journal of Clinical Psychopharmacology, Vol. 45, Núm. 3, pp. 179-196

  7. Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II: A review of fatal outcomes in US Pharmacovigilance data and proposed changes

    Journal of Clinical Psychopharmacology

  8. The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force

    European Psychiatry, Vol. 68, Núm. 1

2024

  1. Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: Comparing the top four reporting countries (US, UK, Canada and Australia)

    Schizophrenia Research, Vol. 268, pp. 165-174

  2. An expert review of clozapine in Eastern European countries: Use, regulations and pharmacovigilance

    Schizophrenia Research, Vol. 268, pp. 53-59

  3. An expert review of clozapine in Latin American countries: Use, monitoring, and pharmacovigilance

    Schizophrenia Research, Vol. 268, pp. 60-65

  4. Clozapine-associated pericarditis and pancreatitis in children and adolescents: A systematic literature review and pharmacovigilance study using the VigiBase database

    Schizophrenia Research, Vol. 268, pp. 118-130

  5. Investigating in VigiBase over 6000 cases of pneumonia in clozapine-treated patients in the context of the literature: focus on high lethality and the association with aspiration pneumonia

    Expert Opinion on Drug Metabolism and Toxicology, Vol. 20, Núm. 8, pp. 857-871

  6. Pharmacovigilance in Action: Utilizing VigiBase Data to Improve Clozapine Safety

    Patient Preference and Adherence , Vol. 18, pp. 2261-2280

  7. Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UK

    Schizophrenia Research, Vol. 268, pp. 175-188